Product overview
Tirzepatide is a dual GIP/GLP-1 receptor agonist used for weight management and blood glucose control in adults with type 2 diabetes. It works by suppressing appetite and slowing gastric emptying, helping reduce food intake and support weight loss.
Benefits
Suppresses appetite and reduces calorie intake; slows gastric emptying and increases feelings of fullness; improves insulin sensitivity and helps regulate blood glucose levels; supports fat metabolism and energy expenditure; promotes significant weight reduction, particularly in individuals with obesity or overweight.
Usage Instructions
Administered once weekly via subcutaneous injection. The typical initial dose is 2.5 mg once weekly for 4 weeks, followed by an increase to 5 mg. Depending on individual tolerance and clinical response, the dose may be further increased to 10 mg or 15 mg for maintenance.
Specific dosage and treatment duration must be determined by a qualified healthcare professional. Tirzepatide should not be used in combination with other GLP-1 receptor agonists.
Intended Audience
Adults with obesity or overweight accompanied by metabolic conditions such as hypertension or dyslipidemia; individuals with type 2 diabetes requiring additional blood glucose control; individuals seeking weight management after insufficient results from dietary and exercise interventions.
Benefits
Suppresses appetite and reduces calorie intake; slows gastric emptying and increases feelings of fullness; improves insulin sensitivity and helps regulate blood glucose levels; supports fat metabolism and energy expenditure; promotes significant weight reduction, particularly in individuals with obesity or overweight.
Usage Instructions
Administered once weekly via subcutaneous injection. The typical initial dose is 2.5 mg once weekly for 4 weeks, followed by an increase to 5 mg. Depending on individual tolerance and clinical response, the dose may be further increased to 10 mg or 15 mg for maintenance.
Specific dosage and treatment duration must be determined by a qualified healthcare professional. Tirzepatide should not be used in combination with other GLP-1 receptor agonists.
Intended Audience
Adults with obesity or overweight accompanied by metabolic conditions such as hypertension or dyslipidemia; individuals with type 2 diabetes requiring additional blood glucose control; individuals seeking weight management after insufficient results from dietary and exercise interventions.